Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CalciMedica, Inc.CALC · Entity 7804 | Director | October 01, 2026 | October 05, 2026 |
| Clearside Biomedical, Inc.CLSD · Entity 82875 | Director | June 20, 2018 | June 21, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CalciMedica, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2036-09-30 | Direct | 20,000 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 20,000 · Balance 20,000 F1: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.
Clearside Biomedical, Inc.
Report date June 20, 2018 · Filed June 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.74 · Expires 2028-06-19 | Direct | 11,250 |
Reported balance
After 2018-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 11,250 · Balance 11,250 F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 21:25 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001674797-26-000007 · form4-10052026_091046.xml · derivative · entry 1 Zaytsev Evgeny · CIK 0001674797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-09-30 F1 · derivative.exercise_date: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 22:44 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001674797-26-000006 · form4-08212026_100845.xml · derivative · entry 3 Zaytsev Evgeny · CIK 0001674797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-08-18 F5 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 22:44 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 1,450,267 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001674797-26-000006 · form4-08212026_100845.xml · derivative · entry 2 Zaytsev Evgeny · CIK 0001674797 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Bering Partners II, L.P. Disclosed balance after: 1,450,267 Underlying: Common Stock · 1,450,267 shares Expires 2031-06-25 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F4 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. F4 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. F3 · ownership.nature: The securities are held by Bering Partners II, L.P. ("Bering II"). Bering Partners II GP, L.L.C. ("Bering II GP") is the general partner of Bering II and may be deemed to have voting and dispositive power over the securities held by Bering II. The Reporting Person, a member of the Issuer's board of directors, and Philip Sawyer are the managing members of Bering II GP and may be deemed to have voting and dispositive power with respect to these securities. Each of Bering II GP, the Reporting Person and Mr. Sawyer disclaim beneficial ownership of the securities held by Bering II, except to the extent of such person's pecuniary interest therein. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 22:44 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantWarrant · Derivative | 1,450,267 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001674797-26-000006 · form4-08212026_100845.xml · derivative · entry 1 Zaytsev Evgeny · CIK 0001674797 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Bering Partners II, L.P. Disclosed balance after: 1,450,267 Underlying: Common Stock · 1,450,267 shares Expires 2027-12-25 F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. F2 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer. F3 · ownership.nature: The securities are held by Bering Partners II, L.P. ("Bering II"). Bering Partners II GP, L.L.C. ("Bering II GP") is the general partner of Bering II and may be deemed to have voting and dispositive power over the securities held by Bering II. The Reporting Person, a member of the Issuer's board of directors, and Philip Sawyer are the managing members of Bering II GP and may be deemed to have voting and dispositive power with respect to these securities. Each of Bering II GP, the Reporting Person and Mr. Sawyer disclaim beneficial ownership of the securities held by Bering II, except to the extent of such person's pecuniary interest therein. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 21:00 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantDirector Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001674797-26-000004 · form4-07072026_090755.xml · derivative · entry 1 Zaytsev Evgeny · CIK 0001674797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-07-01 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest in equal monthly installments over a three year period following the date of grant. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 21:23 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $10.74 | $0.00 |
DisclosureSEC source: 0001209191-18-038990 · doc4.xml · derivative · entry 1 Zaytsev Evgeny · CIK 0001674797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2028-06-19 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2019. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 22:10 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 2,632 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001209191-17-043615 · doc4.xml · derivative · entry 1 Zaytsev Evgeny · CIK 0001674797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,632 Underlying: Common Stock · 2,632 shares Expires 2027-06-29 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 30, 2018. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:39 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 8,618 | $0.00 Strike: $8.81 | $0.00 |
DisclosureSEC source: 0001209191-17-041682 · doc4.xml · derivative · entry 1 Zaytsev Evgeny · CIK 0001674797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,618 Underlying: Common Stock · 8,618 shares Expires 2027-06-21 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.